Literature DB >> 20673780

Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.

Nancy Van Prooyen1, Vibeke Andresen, Heather Gold, Izabela Bialuk, Cynthia Pise-Masison, Genoveffa Franchini.   

Abstract

The non-structural proteins encoded by the orf-I, II, III, and IV genes of the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) genome, are critical for the modulation of cellular gene expression and T-cell proliferation, the escape from cytotoxic T-cells and natural killer cells, and virus expression. In here, we review the main functions of the HTLV-1 orf-I products. The 12kDa product from orf-I (p12) is proteolytically cleaved within the endoplasmic reticulum (ER) to generate the 8kDa protein (p8). At the steady state, both proteins are expressed at similar levels in transfected T-cells. The p12 protein remains in the ER and cis-Golgi, whereas the p8 protein traffics to the cell surface and is recruited to the immunological synapse. The p12 and the p8 proteins have seemingly opposite effects on T-cells; the ER resident p12, modulates T-cell activation and proliferation, whereas p8 induces T-cell anergy. The p8 protein also increases the formation of cellular conduits, is transferred to neighboring T-cells, and increases virus transmission. The requirement for HTLV-1 infectivity of orf-I is demonstrated by the loss of virus infectivity in macaques exposed to an engineered virus, whereby expression of orf-I was ablated. Altogether the current knowledge demonstrates that the concerted activity of p8 and p12 is essential for the persistence of virus infected cells in the host. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673780      PMCID: PMC2967610          DOI: 10.1016/j.mam.2010.07.001

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  89 in total

Review 1.  Nucleocytoplasmic shuttling and the control of NF-AT signaling.

Authors:  J Zhu; F McKeon
Journal:  Cell Mol Life Sci       Date:  2000-03       Impact factor: 9.261

Review 2.  Regulation and isoform function of the V-ATPases.

Authors:  Masashi Toei; Regina Saum; Michael Forgac
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

3.  The HTLV-I orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits.

Authors:  G A Dekaban; A A Peters; J C Mulloy; J M Johnson; R Trovato; E Rivadeneira; G Franchini
Journal:  Virology       Date:  2000-08-15       Impact factor: 3.616

4.  Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission.

Authors:  Nancy Van Prooyen; Heather Gold; Vibeke Andresen; Owen Schwartz; Kathryn Jones; Frank Ruscetti; Stephen Lockett; Prabhakar Gudla; David Venzon; Genoveffa Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-12       Impact factor: 11.205

5.  Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits.

Authors:  Valerio W Valeri; Anna Hryniewicz; Vibeke Andresen; Kathy Jones; Claudio Fenizia; Izabela Bialuk; Hye Kyung Chung; Risaku Fukumoto; Robyn Washington Parks; Maria Grazia Ferrari; Christophe Nicot; Valentina Cecchinato; Frank Ruscetti; Genoveffa Franchini
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

6.  Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles.

Authors:  Vibeke Andresen; Cynthia A Pise-Masison; Uma Sinha-Datta; Marcia Bellon; Valerio Valeri; Robyn Washington Parks; Valentina Cecchinato; Risaku Fukumoto; Christophe Nicot; Genoveffa Franchini
Journal:  Blood       Date:  2011-06-15       Impact factor: 22.113

7.  Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission.

Authors:  J M Taylor; M Brown; M Nejmeddine; K J Kim; L Ratner; M Lairmore; C Nicot
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

8.  Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.

Authors:  C Pique; A Ureta-Vidal; A Gessain; B Chancerel; O Gout; R Tamouza; F Agis; M C Dokhélar
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

Review 9.  Effects of human T-cell leukemia virus type 1 (HTLV-1) p13 on mitochondrial K+ permeability: A new member of the viroporin family?

Authors:  Micol Silic-Benussi; Oriano Marin; Roberta Biasiotto; Donna M D'Agostino; Vincenzo Ciminale
Journal:  FEBS Lett       Date:  2010-02-17       Impact factor: 4.124

Review 10.  Spatial organization and signal transduction at intercellular junctions.

Authors:  Boryana N Manz; Jay T Groves
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-31       Impact factor: 94.444

View more
  28 in total

Review 1.  Molecular mechanisms of HTLV-1 infection and pathogenesis.

Authors:  Junichiro Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2011-09-28       Impact factor: 2.490

2.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

3.  Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase.

Authors:  Katia Ruggero; Alessandro Guffanti; Alberto Corradin; Varun Kumar Sharma; Gianluca De Bellis; Giorgio Corti; Angela Grassi; Paola Zanovello; Vincenzo Bronte; Vincenzo Ciminale; Donna M D'Agostino
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Authors:  Megan M Romeo; Bookyung Ko; Janice Kim; Rebecca Brady; Hayley C Heatley; Jeffrey He; Carolyn K Harrod; Braden Barnett; Lee Ratner; Michael D Lairmore; Ernest Martinez; Bernhard Lüscher; Craig N Robson; Marie Henriksson; Robert Harrod
Journal:  Virology       Date:  2015-01-05       Impact factor: 3.616

5.  First report of HTLV-1 truncated p12 protein in Brazil.

Authors:  Carolina Rosadas; Ana C P Vicente; Louise Zanella; Mauro J Cabral-Castro; José M Peralta; Marzia Puccioni-Sohler
Journal:  Virulence       Date:  2016-12-14       Impact factor: 5.882

6.  Discovery and characterization of auxiliary proteins encoded by type 3 simian T-cell lymphotropic viruses.

Authors:  Jocelyn Turpin; Chloé Journo; Nga Ling Ko; Flore Sinet; Alexandre Carpentier; Amandine Galioot; Dustin Edwards; Anne-Mieke Vandamme; Louis Gazzolo; Madeleine Duc Dodon; Antoine Gessain; Fatah Kashanchi; Ivan Balansard; Romain Lacoste; Renaud Mahieux
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

7.  Human T-Cell Leukemia Virus Type 1 (HTLV-1) bZIP Factor Upregulates the Expression of ICAM-1 To Facilitate HTLV-1 Infection.

Authors:  Ana Laura Fazio; Wesley Kendle; Kimson Hoang; Erica Korleski; Isabelle Lemasson; Nicholas Polakowski
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

8.  Inhibiting HDACs in a preclinical model of HTLV-1-induced adult T-cell lymphoma.

Authors:  Robert Harrod
Journal:  Leuk Res       Date:  2011-08-24       Impact factor: 3.156

Review 9.  Cell-Free versus Cell-to-Cell Infection by Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Type 1: Exploring the Link among Viral Source, Viral Trafficking, and Viral Replication.

Authors:  Hélène Dutartre; Mathieu Clavière; Chloé Journo; Renaud Mahieux
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

10.  The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties.

Authors:  Sébastien A Chevalier; Stéphanie Durand; Arindam Dasgupta; Michael Radonovich; Andrea Cimarelli; John N Brady; Renaud Mahieux; Cynthia A Pise-Masison
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.